Ordering
Available Variants5 mg
CHA.98202-5mg
Price
€74.12
Available – Dispatch in 14 days
25 mg
CHA.98202-25mg
Price
€336.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.98202-5mg | €74.12 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.98202-25mg | €336.80 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C12H13N |
|---|---|
| CAS Number | 185517-74-2 |
| Molecular Weight | 171.24 |
| NACRES | NA.77 |
| PubChem Substance ID | 329825241 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD09029306 |
| Assay | ≥98% (HPLC) |
| Form | (Powder, Film or Oil) |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
GHS09
  GHS07,GHS09
|
|---|---|
| signalword | Warning |
| hcodes | H302,H400 |
| pcodes | P273 - P301 + P312 + P330 |
| Hazard Classifications | Acute Tox. 4 Oral - Aquatic Acute 1 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
TVP1022, also known by its CAS number 185517-74-2, is a synthetic compound with potential therapeutic applications. Research has investigated its effects on various biological systems, including its interaction with specific receptors and enzymes. Studies have shown that TVP1022 exhibits a unique pharmacological profile, characterized by its ability to modulate certain neurotransmitter systems. This compound has been explored as a potential treatment for various neurological and psychiatric disorders, including anxiety and depression. Further investigation is needed to fully elucidate the mechanisms of action and potential therapeutic benefits of TVP1022, as well as to assess its safety and efficacy in clinical settings. Additional research may also reveal new opportunities for the development of TVP1022 as a therapeutic agent, potentially leading to the creation of novel treatments for a range of diseases.
